INSTRUMENT FOR BRAIN CELL IMPLATATION

脑细胞植入仪器

• 批准号: 6529219
• 负责人: CHARLES William SCOUTEN
• 金额: $ 38.48万
• 依托单位: PREFERRED INSTRUMENTS, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6529219
• 关键词: Parkinson's disease; bioengineering /biomedical engineering; biomedical equipment development; brain cell; clinical biomedical equipment; electrophysiology; laboratory rat; method development; microinjections; nervous system transplantation; neurosurgery; stem cells; stroke

DESCRIPTION: (Applicant's abstract) Stereotactic surgery allows procedures on structures deep within the brain, while minimizing damage to tissue above and surrounding the target structure. Traditionally, neurosurgical intervention has involved the removal of pathological tissues. However, an emerging application of neurosurgical technique is the insertion of cells (neurotransplantation), trophic factors, genes, chemo-therapeutics, neuroactive compounds, or other therapeutic agents Neurotransplantation of fresh tissue or neural stem cells holds promise as a method of reconstituting cell populations, supplementing levels of locally produced brain chemicals, and re-establishing neural circuitry. Despite some successes, functional recovery following brain cell injections has to date been modest, with high variability. Marginal functional recovery is directly associated with poor survival of the implanted cells. Improvements in cell survival would contribute to the utility of this potentially powerful therapeutic approach. Numerous studies have demonstrated that cell survival is increased when the injection instrument is smaller and the injection volume is reduced. Cells delivered through a pulled glass micropipette have 250 percent increased survival over cells injected through a 0.5 mm. stainless steel cannula. Commonly used injectors for human surgery are 0.5-1 mm. in diameter. This proposal is to develop an intracerebral microinjection instrument for implanting small volumes of cells deep within the brain, at multiple injection sites, with a minimum of invasive damage. In Phase I, we developed an instrument and demonstrated proof of concept. This device will be scaled to human length, and tested again in animal models of disease. We will perform all testing necessary to obtain FDA approval as an investigational device in humans. PROPOSED COMMERCIAL APPLICATION: Not avaliable

描述：（申请人的摘要）立体定向手术允许在 大脑深处的结构，同时最大限度地减少对大脑上方和周围组织的损害 围绕目标结构。传统上，神经外科干预 涉及去除病理组织。然而，一个新兴的应用 神经外科技术的核心是插入细胞（神经移植）， 营养因子、基因、化疗药物、神经活性化合物或其他 治疗剂新鲜组织或神经干细胞的神经移植 有希望作为一种重建细胞群的方法，补充 局部产生的大脑化学物质的水平，并重建神经 电路。 尽管取得了一些成功，但脑细胞注射后的功能恢复仍然存在 迄今为止，变化不大，变化很大。边际功能恢复是 与植入细胞的存活率低直接相关。改进之处 细胞的存活将有助于这种潜在的强大功能的利用 治疗方法。 大量研究表明，当细胞存活率提高时， 注射仪器更小，注射量减少。细胞 通过拉制玻璃微量移液器输送的量增加了 250% 通过0.5毫米注射的细胞的存活率。不锈钢插管。 人体手术常用的注射器为0.5-1毫米。直径。这 提案是开发一种脑内显微注射仪器 通过多次注射将少量细胞植入大脑深处 地点，具有最小的侵入性损害。在第一阶段，我们开发了一个 仪器和演示的概念证明。该设备将缩放至 人类长度，并在疾病动物模型中再次进行测试。我们将执行所有 获得 FDA 批准作为研究设备所需的测试 人类。 拟议的商业应用： 不可用